David Santamaria

Dr. David Santamaria

ACTION Laboratory, Université de Bordeaux, 33405 Bordeaux, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2017 in Nature
Verified
Journal Article
Closed access
PDF file
PNPatricia Nieto
Patricia Nieto
CAChiara Ambrogio
Chiara Ambrogio
LELaura Esteban-Burgos
Laura Esteban-Burgos
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
MBMaría Teresa Blasco
María Teresa Blasco
David SantamariaDavid Santamaria
David Santamaria

30 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMarie-Julie Nokin
Marie-Julie Nokin
AMAlessia Mira
Alessia Mira
EPEnrico Patrucco
Enrico Patrucco
BRBiagio Ricciuti
Biagio Ricciuti
SCSophie Cousin
Sophie Cousin
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
Selective KRASG12C inhibitors have been developed to covalently lock the oncogene in the inactive GDP-bound state. Two of these molecules, sotorasib and adagrasib, are approved for the treatment of adult patients with KRASG12C-mutated previously treated advanced non-small cell lung cancer. Drug treatment imposes selective pressures leading to the outgrowth of drug-resistant variants. Mass sequencing from patients’ biopsies identified a number of acquired KRAS mutations -both in cis and in trans- in resistant tumors. We demonstrate here that disease progression in vivo can also occur due to adaptive mechanisms and increased KRAS-GTP loading. Using the preclinical tool tri-complex KRASG12C-selective covalent inhibitor, RMC-4998 (also known as RM-029), that targets the active GTP-bound (ON) state of the oncogene, we provide a proof-of-concept that the clinical stage KRASG12C(ON) inhibitor RMC-6291 alone or in combination with KRASG12C(OFF) drugs can be an alternative potential therapeutic strategy to circumvent resistance due to increased KRAS-GTP loading.

1 February 2022 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
FTFabrizio Tabbo'
Fabrizio Tabbo'
CPChiara Pisano
Chiara Pisano
JMJulien Mazieres
Julien Mazieres
LMLaura Mezquita
Laura Mezquita
Ernest NadalErnest Nadal
Ernest Nadal
SOSandra Ortiz-Cuaran
Sandra Ortiz-Cuaran

22 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SHSara Hijazo-Pechero
Sara Hijazo-Pechero
AAAnia Alay
Ania Alay
RMRaúl Marín Montes
Raúl Marín Montes
NVNoelia Vilariño
Noelia Vilariño
Cristina Muñoz-PinedoCristina Muñoz-Pinedo
Cristina Muñoz-Pinedo
XSXavier Solé
Xavier Solé
Recent technological advances and the application of high-throughput mutation and transcriptome analyses have improved our understanding of cancer diseases, including non-small cell lung cancer. For instance, genomic profiling has allowed the identification of mutational events which can be treated with specific agents. However, detection of DNA alterations does not fully recapitulate the complexity of the disease and it does not allow selection of patients that benefit from chemo- or immunotherapy. In this context, transcriptional profiling has emerged as a promising tool for patient stratification and treatment guidance. For instance, transcriptional profiling has proven to be especially useful in the context of acquired resistance to targeted therapies and patients lacking targetable genomic alterations. Moreover, the comprehensive characterization of the expression level of the different pathways and genes involved in tumor progression is likely to better predict clinical benefit from different treatments than single biomarkers such as PD-L1 or tumor mutational burden in the case of immunotherapy. However, intrinsic technical and analytical limitations have hindered the use of these expression signatures in the clinical setting. In this review, we will focus on the data reported on molecular classification of non-small cell lung cancer and discuss the potential of transcriptional profiling as a predictor of survival and as a patient stratification tool to further personalize treatments.

6 August 2020 in JCI Insight
Verified
Journal Article
Closed access
PDF file
MNMarie-Julie Nokin
Marie-Julie Nokin
EDelodie darbo
elodie darbo
CTCamille Travert
Camille Travert
BDBenjamin Drogat
Benjamin Drogat
ALAurélie Lacouture
Aurélie Lacouture
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
Platinum-based chemotherapy in combination with immune-checkpoint inhibitors is the current standard of care for patients with advanced lung adenocarcinoma (LUAD). However, tumor progression evolves in most cases. Therefore, predictive biomarkers are needed for better patient stratification and for the identification of new therapeutic strategies, including enhancing the efficacy of chemotoxic agents. Here, we hypothesized that discoidin domain receptor 1 (DDR1) may be both a predictive factor for chemoresistance in patients with LUAD and a potential target positively selected in resistant cells. By using biopsies from patients with LUAD, KRAS-mutant LUAD cell lines, and in vivo genetically engineered KRAS-driven mouse models, we evaluated the role of DDR1 in the context of chemotherapy treatment. We found that DDR1 is upregulated during chemotherapy both in vitro and in vivo. Moreover, analysis of a cohort of patients with LUAD suggested that high DDR1 levels in pretreatment biopsies correlated with poor response to chemotherapy. Additionally, we showed that combining DDR1 inhibition with chemotherapy prompted a synergistic therapeutic effect and enhanced cell death of KRAS-mutant tumors in vivo. Collectively, this study suggests a potential role for DDR1 as both a predictive and prognostic biomarker, potentially improving the chemotherapy response of patients with LUAD.

1 August 2024 in Cell Reports Medicine
Verified
Journal Article
Open access
MNMarie-Julie Nokin
Marie-Julie Nokin
EDElodie Darbo
Elodie Darbo
ERElodie Richard
Elodie Richard
SJSonia San José
Sonia San José
SHSergio de Hita
Sergio de Hita
David SantamariaDavid Santamaria
David Santamaria
The current targeted therapy for BRAFV600E-mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This regimen extends survival when compared to single-agent treatments, but disease progression is unavoidable. By using whole-genome CRISPR screening and RNA sequencing, we characterize the vulnerabilities of both persister and D/T-resistant cellular models. Oxidative stress together with concomitant induction of antioxidant responses is boosted by D/T treatment. However, the nature of the oxidative damage, the choice of redox detoxification systems, and the resulting therapeutic vulnerabilities display stage-specific differences. Persister cells suffer from lipid peroxidation and are sensitive to ferroptosis upon GPX4 inhibition in vivo. Biomarkers of lipid peroxidation are detected in clinical samples following D/T treatment. Acquired alterations leading to mitogen-activated protein kinase (MAPK) reactivation enhance cystine transport to boost GPX4-independent antioxidant responses. Similarly to BRAFV600E-mutant melanoma, histone deacetylase (HDAC) inhibitors decrease D/T-resistant cell viability and extend therapeutic response in vivo.